Advertisement
BIO vs NVST
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a StrongBuy and NVST is a Hold.
Momentum Indicator for BIO turns positive, indicating new upward trend
BIO saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In 71 of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIO's RSI Indicator exited the oversold zone, 19 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for BIO just turned positive on October 23, 2026. Looking at past instances where BIO's MACD turned positive, the stock continued to rise in 37 of 50 cases over the following month. The odds of a continued upward trend are 74%.
BIO moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BIO crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +3.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in 194 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 63 cases where BIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
BIO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BIO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 19 (best 1 - 100 worst), indicating outstanding price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.422) is normal, around the industry mean (4.142). P/E Ratio (46.363) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.940) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NVST's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for NVST turned positive on October 06, 2026. Looking at past instances where NVST's MACD turned positive, the stock continued to rise in 35 of 49 cases over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on NVST as a result. In 71 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
NVST moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NVST crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +10.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVST advanced for three days, in 171 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVST moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 15 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 63 cases where NVST's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
NVST broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NVST entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. NVST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.314) is normal, around the industry mean (4.964). P/E Ratio (42.661) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.451) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BIO | NVST | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 64 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 87 | 87 | |
PRICE GROWTH RATING 1..100 | 19 | 46 | |
P/E GROWTH RATING 1..100 | 2 | 96 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVST's Valuation (64) in the null industry is in the same range as BIO (90) in the Medical Specialties industry. This means that NVST’s stock grew similarly to BIO’s over the last 12 months.
NVST's Profit vs Risk Rating (100) in the null industry is in the same range as BIO (100) in the Medical Specialties industry. This means that NVST’s stock grew similarly to BIO’s over the last 12 months.
NVST's SMR Rating (87) in the null industry is in the same range as BIO (87) in the Medical Specialties industry. This means that NVST’s stock grew similarly to BIO’s over the last 12 months.
BIO's Price Growth Rating (19) in the Medical Specialties industry is in the same range as NVST (46) in the null industry. This means that BIO’s stock grew similarly to NVST’s over the last 12 months.
BIO's P/E Growth Rating (2) in the Medical Specialties industry is significantly better than the same rating for NVST (96) in the null industry. This means that BIO’s stock grew significantly faster than NVST’s over the last 12 months.
| BIO | NVST | |
|---|---|---|
| RSI ODDS (%) | 6 days ago 68% | 3 days ago 68% |
| Stochastic ODDS (%) | 3 days ago 71% | 3 days ago 75% |
| Momentum ODDS (%) | 3 days ago 76% | 3 days ago 66% |
| MACD ODDS (%) | 3 days ago 74% | 4 days ago 71% |
| TrendWeek ODDS (%) | 3 days ago 66% | 3 days ago 67% |
| TrendMonth ODDS (%) | 3 days ago 69% | 3 days ago 69% |
| Advances ODDS (%) | 5 days ago 65% | 5 days ago 64% |
| Declines ODDS (%) | 7 days ago 69% | 21 days ago 70% |
| BollingerBands ODDS (%) | 3 days ago 68% | 3 days ago 73% |
| Aroon ODDS (%) | 3 days ago 73% | 3 days ago 74% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 2 FA rating(s) are green while NVST’s FA Score has 0 green FA rating(s).
- BIO’s FA Score: 2 green, 3 red.
- NVST’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 6 TA indicator(s) are bullish while NVST’s TA Score has 5 bullish TA indicator(s).
- BIO’s TA Score: 6 bullish, 4 bearish.
- NVST’s TA Score: 5 bullish, 5 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а +2.52% price change this week, while NVST (@Pharmaceuticals: Other) price change was +7.06% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.27%. For the same industry, the average monthly price growth was -8.05%, and the average quarterly price growth was -7.48%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.17%. For the same industry, the average monthly price growth was +1.17%, and the average quarterly price growth was +12.16%.
Reported Earning Dates
BIO is expected to report earnings on Feb 18, 2027.
NVST is expected to report earnings on Feb 10, 2027.
Industries' Descriptions
@Medical/Nursing Services (-3.27% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+2.17% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
NVST and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVST has been closely correlated with ALGN. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVST jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To NVST | 1D Price Change % | ||
|---|---|---|---|---|
| NVST | 100% | +0.84% | ||
| ALGN - NVST | 70% Closely correlated | +4.16% | ||
| XRAY - NVST | 63% Loosely correlated | -6.24% | ||
| BIO - NVST | 57% Loosely correlated | +3.41% | ||
| A - NVST | 55% Loosely correlated | +1.73% | ||
| MTD - NVST | 52% Loosely correlated | +2.57% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FCTE | 28.37 | 0.21 | +0.74% |
| SMI 3Fourteen Full-Cycle Trend ETF (FCTE) | |||
| DEMZ | 46.82 | 0.29 | +0.62% |
| Democratic Large Cap Core ETF (DEMZ) | |||
| KHYB | 23.48 | N/A | N/A |
| KraneShares Asia Pacific High Income USD Bond ETF (KHYB) | |||
| HTD | 23.23 | -0.01 | -0.04% |
| John Hancock Tax-Advantaged Dividend Income Fund | |||
| XLV | 184.80 | -0.11 | -0.06% |
| State Street Health Care Select Sector SPDR ETF (XLV) | |||